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Angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers, and statins have renoprotective effects.
We studied the cellular mechanisms for this effect in
adriamycin-treated mice receiving captopril, losartan,
simvastatin, or their combinations. The mice developed
albuminuria, renal insufficiency, and parenchymal
inflammation/fibrosis accompanied by overexpression of
intrarenal converting enzyme and angiotensin II. Only
captopril consistently improved these abnormalities and
reduced the cortical expression of several proinflammatory
and profibrotic factors including transforming growth
factor-b (TGF-b). These effects were independent of blood
pressure, accompanied by increased urine
N-acetylseryl-aspartyl-lysyl-proline (Ac-SDKP) levels, and the
restoration of renal angiotensin-converting enzyme and
angiotensin II to baseline levels. Losartan or simvastatin
alone or together had no effect, and their addition to
captopril did not enhance protection. In vitro, angiotensin II
stimulated TGF-b in renal tubular cells via mitogen-activated
protein kinase (MAPK) signaling. Captopril or Ac-SDKP
suppressed angiotensin II-induced MAPK activation and
TGF-b secretion. Angiotensin-converting enzyme inhibition
confers renoprotection in adriamycin nephropathy by
reducing intrarenal angiotensin II and augmenting Ac-SDKP
expression that together attenuate MAPK signaling and its
downstream proinflammatory and fibrogenic properties. The
addition of receptor blocker and/or statin failed to potentiate
such effects.
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Emerging evidence from animal and in vitro studies over the
last decade indicates that tubulointerstitial lesions induced by
proteinuria in chronic kidney disease (CKD) may be mediated
through tubular epithelial cell activation.1–7 One constant
feature of proteinuric nephritis is the inevitable emergence of
tubulointerstitial inflammation. The current therapeutic
armamentaria that attempt to lower glomerular protein
hyperfiltration in chronic glomerulonephritides of various
primary and secondary etiologies are more often disappointing
than successful. Thus, an unfulfilled need exists for reducing
the progression of renal failure in patients with CKD.
Angiotensin II (AngII), the key peptide of the renin–an-
giotensin system , is now considered a growth factor that
regulates cell proliferation, apoptosis, and fibrosis in the
kidney.8,9 Antagonizing these effects of AngII has become
a key component of therapeutic strategies to halt progression.
Data from models of renal injury suggest that blockade of
AngII by angiotensin-converting enzyme inhibitor (ACEi), or
AngII receptor subtype 1 (ATR1) blocker not only induces
intraglomerular hemodynamic changes that favor reduction
of glomerular protein ultrafiltration, but also attenuates
inflammatory cell infiltration into the kidney.10,11 These
biological effects translate clinically into reduced rates of
renal function deterioration by ACEi and angiotensin
receptor blockade (ARB) therapy in diabetic and non-
diabetic renal diseases.12–14 In addition, the lipid-lowering
3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors
(statins) also possess profound anti-inflammatory proper-
ties15 and confer renoprotective effects independent of their
lipid-lowering capacity in specific experimental nephropa-
thies.16,17 At the cellular level, statins may downregulate
monocyte chemoattractant protein-1 (MCP-1) in human
glomerular mesangial cells18 and suppress macrophage
infiltration in rat mesangial proliferative nephritis.19
In this study, we explored the renoprotective and anti-
inflammatory potential of combined angiotensin blockade
and statin treatment in a murine model of adriamycin
(ADR)-induced nephropathy, an experimental analogue of
focal glomerulosclerosis in humans.20 In this model, mice
demonstrate features characteristic of chronic progressive
renal disease in humans.21 Overt proteinuria occurs and
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persists from day 5.22 Accumulation of macrophages begins
to appear within the interstitium and glomeruli at week 2,
followed by interstitial T-cell infiltration. By week 4, there is
significant mesangial expansion, increased interstitial volume
and monocytic infiltration, and enhanced cortical expression
of MCP-123 and transforming growth factor-b (TGF-b).24
Apart from MCP-1 and TGF-b, we also examined the
participation of placental growth factor (PLGF), a member of
the vascular endothelial growth factor family, which is
associated with pathologic angiogenesis such as in renal cell
carcinoma.25 Its role in glomerulonephritis remains unclear.
Our preliminary data suggest that PLGF promotes renal
fibrosis via its proinflammatory rather than angiogenic
effects. Indeed, emerging evidence suggests that PLGF plays
a critical role in inflammation through monocyte activation
and expression of cytochemokines.26 These properties make
PLGF a likely candidate in disorders characterized by
intrarenal inflammation, including ADR nephropathy. Our
specific objectives were to investigate the in vivo impact of
applying combined ACE inhibition/ATR1 blockade and statin
treatment on ADR nephropathy, and to dissect the cellular
mechanisms of disease and therapy in cell culture systems.
RESULTS
Physical and biochemical parameters
All animals grew well and were alive prior to killing with
steady body weight. Injection with ADR caused significant
elevation of systolic blood pressure (Figure 1), and marked
albuminuria, hypoalbuminemia, and renal failure after
4 weeks (Figure 2). The various pharmacologic interventions
reduced blood pressure to a similar extent. However, only
captopril treatment consistently alleviated albuminuria and
renal failure. Losartan or simvastatin, alone, combined, or in
addition to captopril, did not produce any synergistic effect.
Use of simvastatin alone increased albuminuria numerically,
albeit not significantly. Urinary levels of N-acetylseryl-
aspartyl-lysyl-proline (Ac-SDKP) were markedly increased
with captopril treatment (Figure 2d).
Morphological changes
Mice with ADR nephrosis exhibited severe lesions in both the
glomerular and tubular compartments (Figure 3). There was
also marked accumulation of interstitial a-smooth muscle
actin (a-SMA) (Figure 4). These lesions were partially
abrogated only by captopril. Losartan or statin alone or
combined had no appreciable effects. Their addition to
captopril did not reduce the extent of injury or fibrosis
further.
Tubular cell proliferation and macrophage infiltration
Mice with ADR nephrosis exhibited marked increase in
proliferating cell nuclear antigen (PCNA)-positive tubular
cells (Po0.001. vs control), which was abrogated only by
protocols that contained captopril. Neither losartan nor
simvastatin alone or combined enhanced the effect of
captopril alone (Figure 5).
Macrophage infiltration into the interstitium was pro-
nounced following ADR induction (Po0.001 vs control).
Treatment response was similar to that observed for tubular
cell proliferation (Figure 6).
Expression of MCP-1, PLGF, TGF-b, and collagen I
Renal cortical western blots of MCP-1, PLGF, TGF-b, and
collagen I were all markedly induced in ADR mice (Figure 7).
Treatment with captopril alone significantly reduced the
intensity of all four immunoblots. Losartan or simvastatin
alone or combined did not reproduce such reduction. Their
addition to captopril, either singly or together, did not
further potentiate the suppressive effects observed with
captopril alone.
Intrarenal ACE and AngII expression
Renal cortical ACE and AngII expression was elevated
compared with controls (Figure 8). In response to captopril
treatment, it was inhibited to levels comparable with baseline
values. Losartan or simvastatin alone or combined did not
inhibit ACE expression in the renal cortex.
Effect of AngII on the phenotype of PTECs
Acute exposure of proximal tubular epithelial cells (PTECs)
to AngII with concentration above 109 M for 6 h upregulated
the transcripts of TGF-b (Figure 9a). AngII had no effect on
the mRNA expression of MCP-1 and PLGF in PTECs (data
not shown). After 24 h of exposure, secretion of TGF-b
protein, but not those of MCP-1 and PLGF, into culture
supernatants was also stimulated with an induction threshold
of 109 M (Figure 9b), which was progressively abrogated by
concurrent treatment with captopril, but not losartan, in a
dose-dependent manner (Figure 10). Similarly, simvastatin
also had no effect on AngII-induced TGF-b release from
PTECs (data not shown).
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Figure 1 | Tailcuff systolic blood pressure at week 4 in control
mice and mice with ADR nephrosis given different
pharmacologic treatments; N¼ 4 in each group. *Po0.001 vs
control, wPo0.05 vs all treatment groups. Box, line across, and
whiskers indicate first and third quartiles, median, and range,
respectively.
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Signal transduction mechanisms
AngII failed to induce Smad2/3 and p38 mitogen-activated
protein kinase (MAPK) expression in PTECs (data not
shown). On the other hand, activation of both MAPK p42/
p44 subunits was evident following exposure to AngII for
30 min (Figure 11). Such activation was abrogated by
pretreatment of cells with the MAPK inhibitor PD98059,
captopril, or Ac-SDKP but not losartan (Figure 11).
Similarly, pretreatment with simvastatin did not influence
AngII-induced MAPK induction (data not shown). To
substantiate the participation of MAPK signaling in mediat-
ing AngII-induced TGF-b secretion, cells were pretreated
with PD98059 30 min before exposure to AngII. This resulted
in significant attenuation of AngII-induced TGF-b secretion
in PTECs (Figure 12). In addition, captopril or Ac-SDKP, but
not losartan, also had similar suppressive effect on AngII-
induced TGF-b secretion.
DISCUSSION
Contemporary renoprotective strategies for chronic protei-
nuric renal disease have been focused on a multidrug
approach combining dual ACEi/ARB blockade and statin
therapy in view of their putative ‘off-label’ anti-inflammatory
actions that are beyond their blood pressure- and lipid-
lowering properties, respectively. In addition to CKD, there is
also promising evidence that avid blockade of the renin–
angiotensin system can suppress cardiovascular inflammation
(reviewed by Ferrario and Strawn27). Results from this study,
however, demonstrate that in murine ADR nephropathy,
which resembles chronic progressive renal disease of focal
glomerulosclerosis in humans, only ACEi consistently alle-
viated proteinuria, improved renal function, and mitigated
parenchymal inflammatory responses and other histologic
markers of tissue injury and fibrosis. These renoprotective
effects were not reproduced by ARB or statin at maximally
effective doses given alone or combined. Furthermore,
combination of ACEi with either ARB or statin, or both,
did not yield any additional benefits that were already
achieved by ACEi alone. Importantly, these findings were not
confounded by differential control of blood pressure, which
was similar across the treatment groups. Of note is the fact
that statin achieved similar blood pressure-lowering effect as
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Figure 2 | Biochemical parameters at week 4 in control mice and mice with ADR nephrosis given different pharmacologic treatments.
(a) Urine albumin excretion expressed as albumin-to-creatinine ratio. *Po0.001 vs control, wP o0.01 vehicle-treated mice. (b) Serum
albumin levels. *Po0.001 vs control, wPo0.01, zPo0.05 vs vehicle-treated mice. (c) Serum creatinine levels. *Po0.001 vs control, wPo0.01,
zPo0.05 vs vehicle-treated mice. (d) Urine Ac-SDKP levels measured from 24-h urine collections. *Po0.05 vs vehicle-treated mice; N¼ 5 in
each group. Box, line across, and whiskers indicate first and third quartiles, median, and range, respectively.
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ACEi or ARB. Such a pleiotropic effect of statin has been
shown in animal and human studies, and the mechanisms
have been postulated to be related to the reversal of
endothelial dysfunction through promotion of endothelial
nitric oxide synthesis, downregulation of ATR1 in vascular
smooth muscle cells, and reduced oxidative stress in the
vasculature (reviewed by Chopra et al.28). More studies,
however, are needed before the antihypertensive role of statins
can be considered conclusive. Another remarkable observa-
tion in our study is the lack of additional blood pressure
reduction by combined therapy vs monotherapy. This may be
related to our use of each therapy at maximally effective doses,
such that the addition of an extra agent produced no further
drop in blood pressure.
Our results contradict mainstream clinical data that
demonstrated superiority of dual therapy over monotherapy
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Figure 3 | Morphological changes. (a–i) (a: control; b: ADRþ vehicle; c: ADRþCap; d: ADRþ Los; e: ADRþ Sim; f: ADRþCapþ Los;
g: ADRþCapþ Sim; h: ADRþ Losþ Sim; i: ADRþCapþ Losþ Sim) Representative renal cortical sections in control animals and mice that
received different drug treatments after the induction of ADR nephrosis. Peroxidase acid–Schiff staining  400. Cap, captopril; Los, losartan;
Sim, simvastatin. Glomerular (j) and tubulointerstitial (k) injuries in renal cortical sections of control animals and mice that received
different drug treatments after the induction of ADR nephrosis were arbitrarily scored on an ordinal scale of 1–5 (see text for definition) in a
blinded manner; N¼ 5 in each group. For (j), *Po0.001 vs control, wPo0.05 vs vehicle-treated mice; for (k), *Po0.01 vs control. Box, line
across, and whiskers indicate first and third quartiles, median, and range, respectively.
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in CKD,29 and experimental data that showed synergistic
renoprotective benefits with triple therapy in uninephrecto-
mized passive Heymann nephritis rats.11 Nevertheless,
emerging clinical data are beginning to question the validity
of combination therapy in CKD. A recent meta-analysis30 of
127 clinical trials with a weighted mean follow-up of over 4
years failed to substantiate any additional renoprotective
action of ACEi or ARB that is beyond blood pressure
lowering in CKD. Indeed, clinical trials that combined rather
low doses of ACEi and ARB resulted in more pronounced
renoprotection than their respective monotherapy,29,31,32
whereas dual therapy was no better than ACEi or ARB alone
given at maximal doses.33,34 Thus, one possible explanation
for our discrepant results may be due to our use of ACEi at
maximal dose.
Although ARB has been shown to suppress renal injury in
experimental CKD,11,35 our results are in agreement with the
previous observation by Nakhoul et al.36 that enalapril but
not losartan reduced proteinuria in ADR rats, and that ACEi/
ARB combination did not provide advantageous antiprotein-
uric responses.24,36 Similarly, Yilmaz et al.37 also reported a
lack of anti-proteinuric effect with losartan in ADR rats.
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Figure 4 | Interstitial a-SMA expression. (a) Computer-analyzed interstitial a-SMA expression in control animals and mice that received
different drug treatments after the induction of ADR nephrosis; N¼ 5 in each group. *Po0.001 vs control, wPo0.01, zPo0.05 vs vehicle-treated
mice. Box, line across, and whiskers indicate first and third quartiles, median, and range, respectively. (b–j) (b: control; c: ADR; d: ADRþCap; e:
ADRþ Los; f: ADRþ Sim; g: ADRþCapþ Los; h: ADRþCapþ Sim; i: ADRþ Losþ Sim; j: ADRþCapþ Losþ Sim) Representative
photomicrographs of a-SMA staining. Cap, captopril; Los, losartan; Sim, simvastatin  400.
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Therefore, it seems, whereas dual therapy had additive
renoprotective effects in passive Heymann nephritis,11,17 such
synergism was not reproduced in the ADR model.
Despite mounting efforts to include statins into a paradigm
of multi-drug approach for CKD,11,38 simvastatin monother-
apy or combined with ACEi/ARB failed to protect ADR mice
from renal injury. This is unexpected in view of experimental
evidence demonstrating its immunosuppressive effects.15
Arguably, our results lend support to a recent meta-analysis39
of 21 randomized clinical trials including over 39 000 patients
that the renoprotective benefits of statin therapy were not
significant in diabetic or hypertensive CKD. Even the benefits
that were observed in the subgroup of patients with
cardiovascular disease were only modest. Another point of
interest is that statin therapy invariably induced a small, albeit
insignificant, increase in albuminuria in ADR mice. This is in
line with the occurrence of proteinuria in humans taking high-
dose statins, and may be related to impaired receptor-
mediated endocytosis of albumin by the proximal tubule as
a result of reduced mevalonate activity that is required for the
generation of isoprenoid pyrophosphates necessary for
receptor-mediated endocytosis.40,41
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Figure 5 | Tubular cell proliferation. (a) Number of PCNAþ tubular cells per high-power field (HPF) in control animals and mice that
received different drug treatments after the induction of ADR nephrosis; N¼ 5 in each group. *Po0.001 vs control, wPo0.01, zPo0.05 vs
vehicle-treated mice. Box, line across, and whiskers indicate first and third quartiles, median, and range, respectively. (b–j) (b: control; c: ADR;
d: ADRþCap; e: ADRþ Los; f: ADRþ Sim; g: ADRþCapþ Los; h: ADRþCapþ Sim; i: ADRþ Losþ Sim; j: ADRþCapþ Losþ Sim)
Representative photomicrographs of staining for PCNA. Cap, captopril; Los, losartan; Sim, simvastatin  400.
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Renal cortical ACE expression was reduced to baseline
levels with ACEi monotherapy in ADR mice. Use of statin
alone or combined with ACEi/ARB had no apparent effect.
Although ACE protein levels and ACE activity are not
equivalent, recent data on the impact of statins on the latter
are conflicting. In rats, statins inhibited ACE activity in
passive Heymann nephritis kidneys11 and pressure-over-
loaded hypertrophic hearts.42 In the passive Heymann
nephritis model,11 statins appeared to have a robust effect
when given on a background of ACEi plus ARB in which ACE
activity was suppressed below control values. However, the
investigators did not show the effect of ARB alone, which has
been reported recently to have no effect on cardiac ACE
activity in dilated cardiomyopathic hamsters.43 In humans,
a lack of inhibitory effect of simvastatin on plasma ACE
activity has been reported.44 Further studies are needed to
clarify the role of statin on ACE activity in the setting of
chronic glomerulonephritis.
As renal prognosis in CKD correlates much more with
lesions in the tubulointerstitium than those in the glome-
rulus, and because of ample evidence implicating that
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Figure 6 | Infiltration of macrophages. Number of interstitial
F4/80þ macrophages per high-power field (HPF) were counted in
control animals and mice that received different drug treatments
after the induction of ADR nephrosis; N¼ 5 in each group. *Po0.001
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Figure 7 | Renal cortical western blots in control animals and mice that received different drug treatments after the induction of
ADR nephrosis. (a) MCP-1, *Po0.001 vs control, wPo0.01, zPo0.05 vs vehicle-treated mice. (b) PLGF, *Po0.01 vs control, wPo0.05, zPo0.01 vs
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wPo0.05 vs vehicle-treated mice. A representative electrophoretogram is shown at the top of the quartile plot for each immunoblot; N¼ 5 in
each group. Box, line across, and whiskers indicate first and third quartiles, median, and range, respectively.
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tubulointerstitial injury is mainly orchestrated by signals
originating from PTECs (reviewed by Abbate et al.45), we
employed PTECs to study the in vitro effects of AngII and the
role of ACEi/ARB/statin. Interestingly, the threshold AngII
concentration (4109 M) required to induce TGF-b is also in
line with our recent observation of the same threshold to
induce apoptosis in renal tubular cells via ATR2 expression.46
Indeed, ADR-induced suppression of ATR224 may be another
mechanism of injury driven by ADR, but this requires further
studies. Furthermore, our finding of AngII-stimulated TGF-b
in PTECs through MAPK p42/p44 signaling independent of
Smad2/3 pathways is in agreement with the observation of
MAPKSmad signaling cross talk pathways.47
Although suppression of intrarenal AngII levels by
captopril is an expected finding, the observation that ACE
inhibition but not ATR1 blockade ameliorated TGF-b
overexpression implies that ACEi may possess other biologic
effects in addition to suppressing AngII production. That
captopril blunted AngII-induced TGF-b in PTECs suggests
that its in vitro effect is not due to inhibition of ACE activity
toward angiotensin peptides, but is the consequence of either
a specific property of captopril, such as an antioxidant effect
from its thiol function, or the inhibition of bradykinin
degeneration. The former explanation is not likely, as
enalapril also achieved similar efficacy as captopril in ADR
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Figure 9 | Tubular expression of TGF-b mRNA after acute
exposure to AngII. (a) mRNA expression. Confluent, growth-arrested
cells were exposed for 6 h to control medium alone or supplemented
with AngII at 1012–106 M. Results are means±s.d. of five
experiments. *Po0.001 vs control. (b and c) Protein secretion.
Confluent, growth-arrested cells were exposed to control medium
alone or supplemented with AngII at 1012–106 M for 24 h and at
108 M for 0–48 h. TGF-b levels in culture supernatants were assayed
by enzyme-linked immunosorbent assay and corrected for cell
number. Results are means±s.d. of five experiments and expressed
as percentage of medium control. *Po0.001 vs control.
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nephrosis.36 The latter explanation is also unlikely, as the
antiproteinuric effect of ACE inhibition in ADR rats has been
shown to be independent of bradykinin.48
Another plausible antifibrotic mechanism of captopril is
through its blockade of hydrolysis of Ac-SDKP, a natural
inhibitor of hematopoietic stem cell proliferation and a
natural substrate of ACE. Our results confirmed that
captopril increased renal Ac-SDKP levels in vivo as reflected
by increased urinary Ac-SDKP excretion, and that, in vitro,
Ac-SDKP prevented AngII-induced p42/44 MAPK activation
and TGF-b release. Similar protective mechanisms are also
observed in aldosterone salt-induced hypertensive rats in
which the application of Ac-SDKP-blocking antibody con-
firmed that Ac-SDKP mediated the antifibrotic effect of
captopril and resulted in decreased inflammatory cell
infiltration and p42/44 MAPK activation in the heart and
the kidneys.49 The cardiac antifibrotic effect of Ac-SDKP was
also observed in AngII-induced hypertensive rats.50
On the other hand, AngII did not induce MCP-1 or PLGF
in PTECs or mesangial cells in vitro, but ACEi did suppress
cortical expression of these cytokines and intrarenal inflam-
mation in vivo. This implies that the inflammatory
component of ADR nephropathy may be mediated via
additional cell types such as podocytes, infiltrating cells, or
the systemic effect of ADR, which are also susceptible to the
anti-inflammatory effects of ACEi. The dissection of such
interaction requires further investigation.
CONCLUSION
ACEi treatment achieved significant renoprotection in ADR
nephropathy through suppression of AngII-induced proin-
flammatory and profibrotic mechanisms, but its combination
with ARB and/or statin failed to bestow any additive
advantages. Our findings may explain the stark fact that
many patients with CKD still go into ESRD despite dual
renin–angiotensin system blockade plus statin therapy and
raise doubts on whether this multidrug approach is efficacious
for all forms of chronic nephropathies. These have implica-
tions for rationing drug prescriptions and for the design of
future studies to discover novel renoprotection strategies.
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Figure 11 | Detection of phospho-p42 and phospho-p44 subunits of MAPK. Western blot analyses of cell extracts of PTECs probed
with anti-phospho p42/p44 MAPK following 30-min exposure to 108 M AngII, PD98059 (25 mM, added 30 min before the addition of AngII),
captopril (100 nM, added 30 min before the addition of AngII), losartan (100 nM, added 30 min before the addition of AngII), or Ac-SDKP
(10 nM, added 30 min before the addition of AngII). A loading control using anti-unphosphorylated protein was included. The results shown are
representative of three independent experiments.
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Figure 10 | Effect of captopril or losartan on AngII-induced TGF-b
secretion in PTECs. Confluent, growth-arrested cells were exposed
for 24 h to medium containing 108 M AngII in the presence of
captopril or losartan at 0–104 nM. At the end of the incubation, TGF-b
levels in culture supernatants were assayed by enzyme-linked
immunosorbent assay and corrected for cell number. Results are
means±s.d. of five experiments and expressed as percentage of
medium control. *Po0.001 vs control.
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Figure 12 | Effect of MAPK or ACE inhibition, ATR1 blockade, or
exogenous Ac-SDKP on AngII-induced TGF-b secretion in PTECs.
Confluent, growth-arrested PTECs were treated for 24 h with medium
alone (control), AngII (108 M), PD98059 (25 mM, added 30 min before
the addition of AngII), captopril (100 nM, added 30 min before the
addition of AngII), losartan (100 nM, added 30 min before the addition
of AngII), or Ac-SDKP (10 nM, added 30 min before the addition of
AngII). At the end of incubation, TGF-b levels in culture supernatants
were assayed by enzyme-linked immunosorbent assay and corrected
for cell number. Results are means±s.d. of five experiments and
expressed as percentage of medium control. Open and hatched bars
are medium and pharmacologic controls, respectively. *Po0.001 vs
medium control, wPo0.001 vs cells treated with AngII alone.
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MATERIALS AND METHODS
Antibodies and reagents
Antibodies were rat anti-mouse F4/80 (Serotec, Oxford, UK);
monoclonal anti-a-smooth muscle actin (clone 1A4; Sigma,
St Louis, MO, USA); monoclonal anti-mouse PLGF-2 (Sigma);
monoclonal anti-mouse ACE (Chemicon International, Temecula,
CA, USA); goat anti-mouse MCP-1, goat anti-AngII, rabbit anti-
mouse TGF-b (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
rabbit anti-collagen I (Fitzgerald Industries International Inc.,
Concord MA, USA); monoclonal anti-PCNA (clone PC-10, Dako,
Carpinteria, CA, USA). Isotype-matched antibodies were used as
negative controls. Losartan and simvastatin were obtained from
Merck Research Laboratories (Merck & Co. Inc., Rahway, NJ, USA).
Ac-SDKP was from Calbiochem (Darmstadt, Germany).
Dulbecco’s modified Eagle’s medium and Ham’s F12 medium
and fetal bovine serum were from Life Technologies (Rockville, MD,
USA). Enzyme immunoassay kit for detecting TGF-b was from R&D
Systems (Minneapolis, MN, USA). Antibody to phospho-p42/p44
MAPK and anti-phospho-p38 MAPK were from Cell Signaling
Technology (Beverly, MA, USA). The extracellular signal-regulated
kinase 1/2 (ERK 1/2) inhibitor PD98059 was from Sigma.
Experimental design
All work with mice was approved by the Committee on the Use of
Live Animal in Teaching and Research of the University of Hong
Kong and were performed in accordance with the NIH Guide for the
Care and Use of Laboratory Animals. BALB/c mice weighing 24–26 g
were randomly assigned to sham (n¼ 5) and experimental groups
(eight groups; n¼ 5 each). Experimental mice received a single
intravenous injection of ADR (Ebewe Arzneimittel GmbH, Unter-
ach, Austria) diluted with 0.9% saline to a final dose of 11 mg kg1.
Control mice received the same volume of 0.9% saline. Two days
after injection, mice received either captopril (30 mg kg1 day1),
losartan (20 mg kg1 day1), or simvastatin (10 mg kg1 day1) by
oral gavage, alone or combinations of the three drugs, or vehicle
alone. The doses of drugs were based on previous studies.51,52
During the last week of the study, systolic blood pressures were
measured using a computerized tailcuff system (Visitech Systems,
Cary, NC, USA) in conscious mice with a photoelectric sensor. Mice
were adapted to the apparatus 1 week before the measurement. Prior
to killing on day 28, 24-h urine samples were collected in a
metabolic cage. Blood samples were taken by transthoracic cardiac
puncture after anesthesia. The kidneys were rapidly removed and
weighed. The cortex from transversely bisected left kidneys was
snap–frozen in liquid nitrogen and stored at 701C for protein and
total RNA extraction. That of the right kidneys was fixed with 10%
buffered formalin and embedded in paraffin for histological
evaluation.
Biochemical analyses of serum and urine samples
Albumin and creatinine concentration in urine and serum samples
were measured by mouse albumin enzyme-linked immunosorbent
assay quantitation kit (Bethyl Laboratories Inc., Montgomery, TX,
USA) and creatinine test kit (Stanbio Laboratory, Boerne, TX, USA)
according to the manufacturer’s protocols.
N-acetyl-SDKP assay
Urine was collected directly from mice bladders in a pre-chilled syringe
containing 10ml of 10mmol l1 lisinopril. Ac-SDKP in urine was
measured using a commercially available enzyme immunoassay kit
(SPI-BIO Massy, France) according to the manufacturer’s instructions.
Renal histopathology
Paraffin-embedded sections (4-mm thick) were deparaffinized with
xylene and rehydrated through a descending ethanol gradient.
Histology was examined following periodic acid–Schiff staining, and
graded according to published standards.17,53 Twenty high-power
fields ( 400) of renal cortex were randomly selected for assessing
tubular (atrophy, casts, and vacuolization) and interstitial changes
(fibrosis and inflammation) and graded from 0 to 5þ (tubuloin-
terstitial area in the cortex was graded as follows: 0, normal; 1, area
of interstitial inflammation and fibrosis, tubular atrophy, and
vacuolization involving o10%; 2, lesion area between 10–20%; 3,
lesion area between 20–30%; 4, lesion area between 30–40%; and 5,
lesions involving 440% of the field). Fifty randomly selected
glomeruli were assessed for glomerular damage (well-developed
exudative, mesangial proliferation and glomeruli hypertrophy), and
graded as follows: 0, normal; 1, slight glomerular damage of the
mesangial matrix and/or hyalinosis with focal adhesion involving
o10% of the glomerulus; 2, sclerosis of 10–20%; 3, sclerosis of
20–30%; 4, sclerosis of 30–40%; and 5, sclerosis 440% of the
glomerulus. All scoring was performed in a blinded manner.
Immunohistochemical analysis
Immunoperoxidase staining for interstitial F4/80þ macrophages,
PCNA, and (a-SMA was performed on formalin-fixed paraffin
sections (4mm). Briefly, sections were incubated with 0.5% H2O2.
Nonspecific binding was blocked with blocking buffer (5% normal
goat serum and 3% bovine serum albumin in phosphate-buffered
saline) for 30 mins. The sections were incubated with primary
antibodies (10 mg ml1) overnight. The bound rat anti-F4/80 was
detected with peroxidase anti-rat antibody and visualized in brown
using DAB substrate. The bound rabbit antibodies were visualized in
brown using the Dako Envision Plus System. Immunostained
interstitial F4/80þ macrophages and tubular PCNAþ cells were
counted for 25 high-power ( 400) interstitial/tubular fields and
expressed as number of positive cells per field. Interstitial a-SMA
was assessed from the percentage area of immunostaining within the
interstitium by computer image analysis. Isotype-matched anti-
bodies corresponding to the primary antibodies used were used as
negative controls. All scoring was performed in a blinded manner.
Immunoblotting of cytokines in kidney
Total protein extracts were prepared from the cortex using
solubilization buffer containing 10 mM Tris, 150 mM NaCl, 5 mM
ethylenediaminetetraacetic acid, 0.2 mM. phenylmethylsulfonyl
fluoride, 1% Triton X-100 and complete protease inhibitors. The
extracts (5 mg) were electrophoresed through 15% SDS-PAGE gel.
For immunoblotting, the proteins were transferred to polyvinyl-
idene difluoride membranes and probed with goat anti-mouse
MCP-1 (1:500 diluted), goat anti-AngII (1:500 diluted), rabbit anti-
mouse TGF-b (1:1000 diluted), rabbit anti-mouse collagen I (1:200
diluted), anti-mouse ACE (1:1000 diluted), anti-mouse PLGF
(1:1000 diluted), or goat anti-mouse actin (1:1000 diluted) in
phosphate-buffered saline–Tween for 16 h. The membrane was
washed and incubated for 2 h at room temperature with peroxidase-
labeled anti-goat, anti-mouse, or anti-rabbit immunoglobulins and
the antigen–antibody reaction was detected with ECL plus
chemiluminescence (Amersham Pharmacia Biotech, Arlington, IL,
USA). The immunoblots were densitometrically reported as ratio of
average arbitrary integrated values (units) after normalization with
actin values.
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In vitro studies
Cell culture. Human PTECs were isolated as previously
described,7 and grown in Dulbecco’s modified Eagle’s medium and
Ham’s F12 medium supplemented with glutamine (2 mmol l1),
penicillin (100 U/ml), streptomycin (100mg ml1), hydrocortisone
(40 ng ml1), and 10% fetal bovine serum at 371C in 5% CO2 and
95% air.
Effect of AngII on cytokine gene and protein expression
in PTECs. PTECs grown to log phase were subcultured onto six-
well culture plates (106 cells per well), and growth-arrested for 24 h.
Cells were incubated with AngII (1012–106 M) for 6 or 24 h at 371C.
In parallel experiments, PTECs were cultured with AngII (108 M) for
various time points (12–48 h). Cells were harvested for total RNA
extraction, whereas culture supernatants were stored at 701C.
Specific primer sequence for TGF-b was designed from GenBank
sequence (M 38449). For quantification, GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) was included as an internal control.
Effect of captopril, losartan, or Ac-SDKP. PTECs were
incubated with captopril or losartan (1–10 000 nM) in the presence
of AngII (108 M), for 24 h at 371C. Supernatants were collected and
stored at 701C before determination of TGF-b levels. In separate
experiments, PTECs were incubated with PD98059 (25 mM),
captopril (100 nM), losartan (100 nM), or Ac-SDKP (10 nM) in the
presence or absence of AngII (108 M), for 30 min or 24 h at 371C.
Cells (30 min incubation) were collected to prepare total lysate for
immunoblotting. Culture supernatants were collected (24 h incuba-
tion) for determination of TGF-aˆ levels.
Western blot analyses of signal transduction mechanisms. Im-
munoblotting was performed as described previously.54 Briefly, 10mg of
total protein from the extract was electrophoresed through a 15% SDS-
PAGE gel and transferred to a polyvinylidene difluoride membrane
before probing with anti-phospho-p42/p44 MAPK (1:1000 diluted),
anti-phospho-p38 MAPK (1:500 diluted), or goat polyclonal antibodies
(1:200 diluted) to pSmad2/3 (Santa Cruz Biotechnology). A loading
control probing with unphosphorylated p42/p44, p38, or Smad2/3
antibodies was included. The membrane was detected with ECL Plus
Western blotting detection reagents.
Statistical analysis
Animal data are presented as median and quartile range, and
statistical differences were analyzed by the Kruskal–Wallis test for
non-parametric data with Dunn’s multiple comparisons post-test
using GraphPad PRISM version 5.00 for Windows (GraphPad
Software Inc., San Diego, CA, USA). In vitro data are expressed as
mean±s.d., and statistical differences were assessed by a single
factor variance (ANOVA) followed by unpaired t-test with
Bonferroni correction for multiple comparisons. P-values o0.05
were considered significant.
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